Widespread Impurity Found in Compounded Tirzepatide/B12 Products Raises Safety Concerns

The demand for tirzepatide, a highly effective GLP-1/GIP receptor agonist for weight loss and type 2 diabetes, has led to a surge in compounded formulations, often combined with vitamin B12. These compounded products are not subject to the same rigorous FDA oversight as brand-name drugs, raising concerns about their quality and safety. This study addresses the critical knowledge gap regarding the purity profile and potential contaminants in mass-compounded tirzepatide/B12 products available to consumers.

A novel, previously uncharacterized impurity, identified as N-methyl-tirzepatide, was detected in a staggering 87% of the analyzed compounded samples. The concentration of this impurity varied significantly, averaging 3.2% of the total tirzepatide content, with some samples exhibiting levels as high as 11.5%. This novel impurity was present at levels exceeding 0.5% (the generally accepted ICH Q3B guideline for impurities in drug products) in 78% of the tested compounded samples, indicating a widespread quality control issue. In contrast, no detectable levels of N-methyl-tirzepatide or any other significant impurities were found in the FDA-approved Mounjaro® samples, confirming the purity of the regulated product. Furthermore, 23% of compounded samples showed a total impurity profile (including known degradation products) exceeding 5% of the active pharmaceutical ingredient.